Premium
Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum‐based chemoradiotherapy treatment
Author(s) -
Duran Goretti,
Aguín Santiago,
Cruz Raquel,
Barros Francisco,
Giráldez José María,
Bernárdez Beatriz,
LópezLópez Rafael,
Carracedo Ángel,
Lamas María Jesús
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25754
Subject(s) - ercc1 , gstp1 , chemoradiotherapy , oncology , single nucleotide polymorphism , medicine , head and neck cancer , toxicity , snp , cisplatin , allele , genotype , radiation therapy , chemotherapy , biology , nucleotide excision repair , gene , genetics , dna repair
Background Platinum‐based chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck squamous‐cell carcinomas (HNSCC), and most patients experience serious toxicities. The aim of this study was to investigate the association between candidate genes involved in radiation/platinum pathways and acute toxicity of CRT to determine the predictive value of these polymorphisms for toxicity. Methods Thirty‐six selected single nucleotide polymorphisms (SNPs) in 29 genes were genotyped in 110 patients treated with cisplatin‐based CRT. DNA was obtained from blood samples, and SNP analysis was performed using a MassARRAY iPLEX Gold (Sequenom) method. Results Patients with ERCC1 rs11615‐C allele ( P = .0066), ERCC1 rs735482‐C allele ( P = .0204), and ERCC4 rs1799801‐C allele ( P = .0286) had lower risk of grade 2‐3 hematologic toxicity. In addition, the presence of G allele of GSTP1 was associated with a significantly lower risk of severe dysphagia ( P = .0004). Conclusion Polymorphisms in ERCC1 and GSTP1 may act as prognostic factors of acute toxicity during treatment with CRT in HNSCC patients.